OPTHEA LIMITED - Announcements

0.00%

60.0¢

Market Cap $820.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

OPT	Appendix 3B		06/08/18	158.8KB	Share
OPT	Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME	PRICE SENSITIVE	30/07/18	112.93KB	Share
OPT	Opthea Meets Primary Safety Objective in DME Phase 1b trial	PRICE SENSITIVE	26/07/18	116KB	Share
OPT	Opthea reaches mid-way in recruitment for Ph2b wAMD trial	PRICE SENSITIVE	02/07/18	146.94KB	Share
OPT	Appendix 3B		27/06/18	159.17KB	Share
OPT	Change in substantial holding		30/05/18	117.68KB	Share
OPT	Ceasing to be a substantial holder for ANP		11/05/18	96.61KB	Share
OPT	Opthea Doses wAMD Patients in Europe and Israel	PRICE SENSITIVE	27/03/18	73.52KB	Share
OPT	Opthea Half Year Report and Accounts	PRICE SENSITIVE	19/02/18	449.32KB	Share
OPT	Appendix 3B		12/01/18	158.82KB	Share
OPT	Opthea Corporate Presentation - January 2018		08/01/18	2.64MB	Share
OPT	Opthea Receives A$2.7m R&D Tax Incentive	PRICE SENSITIVE	08/01/18	65.84KB	Share
OPT	Opthea Initiates OPT-302 Diabetic Macular Edema Trial	PRICE SENSITIVE	03/01/18	398.83KB	Share
OPT	Change in substantial holding		22/12/17	170.88KB	Share
OPT	Change in substantial holding (Full copy)		19/12/17	1.04MB	Share
OPT	Opthea Doses First Patient in OPT-302 wAMD Ph2b trial	PRICE SENSITIVE	19/12/17	302.75KB	Share
OPT	Change in substantial holding		19/12/17	1003.26KB	Share
OPT	Appendix 3B		15/12/17	162.11KB	Share
OPT	Results of Meeting		23/11/17	40.86KB	Share
OPT	Opthea CEO Presentation to the 2017 AGM		23/11/17	2.02MB	Share
OPT	Opthea Chairman's Address to the 2017 AGM		23/11/17	71.99KB	Share
OPT	Appendix 3B		21/11/17	162.29KB	Share
OPT	Notice of Annual General Meeting and Proxy Form		23/10/17	884.19KB	Share
OPT	Opthea Granted Key United States Patent Covering OPT-302	PRICE SENSITIVE	31/08/17	73.63KB	Share
OPT	Appendix 4G and Corporate Governance Statement 2017		30/08/17	268.62KB	Share
OPT	Opthea Appendix 4E and Annual Report 2017	PRICE SENSITIVE	30/08/17	6.7MB	Share
OPT	Opthea Presents Further Positive Data from OPT-302 Ph1/2A	PRICE SENSITIVE	15/08/17	260.85KB	Share
OPT	Opthea presentation for Ophthalmology Innovation Summit		11/08/17	1.18MB	Share
OPT	Opthea Presents at the Ophthalmology Innovation Summit		11/08/17	302.32KB	Share
OPT	Opthea to present at the ASRS Annual Meeting and the OIS		09/08/17	261.52KB	Share
OPT	Opthea to Present at Wedbush PacGrow Conference		01/08/17	65.34KB	Share
OPT	Opthea Allowed Key Patent for OPT-302 in United States	PRICE SENSITIVE	06/07/17	75.74KB	Share
OPT	Appendix 3B		30/06/17	147.89KB	Share
OPT	Change of Director's Interest Notice - GK		09/05/17	76.41KB	Share
OPT	Change of Director's Interest Notice - MB		09/05/17	88.64KB	Share
OPT	Appendix 3B		03/05/17	155.8KB	Share
OPT	Opthea Completes A$45 Million Capital Raising	PRICE SENSITIVE	28/04/17	74.07KB	Share
OPT	Change of Director's Interest Notice - MS		27/04/17	88.27KB	Share
OPT	Ceasing to be a substantial holder		21/04/17	131.77KB	Share
OPT	Change in substantial holding		18/04/17	6.39MB	Share
OPT	Placement Cleansing Statement		12/04/17	54.18KB	Share
OPT	Appendix 3B		12/04/17	221.2KB	Share
OPT	Opthea Entitlement Offer Notice to Ineligible Shareholders		10/04/17	90.11KB	Share
OPT	Opthea Retail Entitlement Offer Booklet		10/04/17	14.78MB	Share
OPT	ASX Notice - Accelerated Non-Renounceable Entitlement Offer		05/04/17	364KB	Share
OPT	Opthea Successfully Completes Institutional Capital Raising	PRICE SENSITIVE	05/04/17	277.24KB	Share
OPT	Entitlement Offer Cleansing Statement		03/04/17	92.52KB	Share
OPT	Appendix 3B		03/04/17	222.98KB	Share
OPT	Opthea A$45M Equity Raising Launch Presentation		03/04/17	902.34KB	Share
OPT	Opthea Launches A$45M Financing for Clinical Development	PRICE SENSITIVE	03/04/17	69.48KB	Share
OPT	Opthea Phase 1/2A wet AMD Trial Update Presentation		03/04/17	1.57MB	Share
OPT	Opthea Reports Positive Phase 1/2A Clinical Results	PRICE SENSITIVE	03/04/17	93.12KB	Share
OPT	Trading Halt	PRICE SENSITIVE	03/04/17	281.48KB	Share
OPT	Opthea to Host Update on OPT-302 Phase 1/2A wAMD Trial		31/03/17	257.13KB	Share
OPT	Trading Halt	PRICE SENSITIVE	30/03/17	269.41KB	Share
OPT	Opthea Receives EU Regulatory Feedback for OPT-302 Program	PRICE SENSITIVE	20/03/17	259.56KB	Share
OPT	Ceasing to be a substantial holder		13/03/17	104.46KB	Share
OPT	Opthea Completes FDA Meeting to Inform OPT-302 Program	PRICE SENSITIVE	09/03/17	259.31KB	Share
OPT	Opthea Half Year Report and Accounts	PRICE SENSITIVE	21/02/17	732.82KB	Share
OPT	Change in substantial holding		14/02/17	129.15KB	Share
OPT	Appendix 3B		06/02/17	154.22KB	Share
OPT	Opthea Corporate Presentation during JPMorgan Conference		09/01/17	2.19MB	Share
OPT	Results of Meeting		28/11/16	44.23KB	Share
OPT	Opthea CEO Presentation to the 2016 AGM		28/11/16	1.75MB	Share
OPT	Opthea Chairman's Address to the 2016 AGM		28/11/16	56.28KB	Share
OPT	Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial	PRICE SENSITIVE	21/11/16	257.39KB	Share
OPT	Notice of Annual General Meeting and Proxy Form-OPT.AX		28/10/16	573.32KB	Share
OPT	Opthea receives $2.6M R&D tax incentive-OPT.AX	PRICE SENSITIVE	17/10/16	53.39KB	Share
OPT	Appendix 3B-OPT.AX		10/10/16	154.08KB	Share
OPT	Opthea Ph1 wAMD data presented at EURETINA 2016-OPT.AX		12/09/16	258.87KB	Share
OPT	Appendix 4G and Corporate Governance Statement 2016-OPT.AX		29/08/16	193.92KB	Share
OPT	Appendix 4E and Annual Report 2016-OPT.AX	PRICE SENSITIVE	29/08/16	6.82MB	Share
OPT	Opthea to Present at Ophthalmology Innovation Summit in US-OPT.AX		08/08/16	301.01KB	Share
OPT	Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX	PRICE SENSITIVE	26/07/16	284.72KB	Share
OPT	Opthea to Host Conference Call Update on wetAMD Trial-OPT.AX		25/07/16	256.34KB	Share
OPT	Change of Director's Interest Notice - MB-OPT.AX		05/07/16	74.93KB	Share
OPT	Appendix 3B-OPT.AX		18/05/16	157.11KB	Share
OPT	Change in substantial holding from OPT,OPT-ANP.AX		16/05/16	63.23KB	Share
OPT	Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD-OPT.AX	PRICE SENSITIVE	05/05/16	270.78KB	Share
OPT	Opthea Ph1 wAMD Trial with OPT-302 Meets Primary Objective-OPT.AX	PRICE SENSITIVE	21/04/16	322.48KB	Share
OPT	Change of Director's Interest Notice - GK-OPT.AX		07/04/16	76.08KB	Share
OPT	Change of Director's Interest Notice - MS-OPT.AX		07/04/16	75.67KB	Share
OPT	Change of Director's Interest Notice - MB-OPT.AX		07/04/16	74.15KB	Share
OPT	Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial	PRICE SENSITIVE	30/03/16	318.78KB	Share
OPT	Results of the Extraordinary General Meeting		07/03/16	81.87KB	Share
OPT	CEO's Presentation to the EGM		07/03/16	1.71MB	Share
OPT	Chairman's Address to the EGM		07/03/16	53.8KB	Share
OPT	Half Year Report and Accounts	PRICE SENSITIVE	26/02/16	943.53KB	Share
OPT	Notice of Extraordinary General Meeting/Proxy Form		05/02/16	607.33KB	Share
OPT	Becoming a substantial holder		30/12/15	150.8KB	Share

OPT Appendix 3B
06/08/18		158.8KB	Share
OPT Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME
30/07/18	PRICE SENSITIVE	112.93KB	Share
OPT Opthea Meets Primary Safety Objective in DME Phase 1b trial
26/07/18	PRICE SENSITIVE	116KB	Share
OPT Opthea reaches mid-way in recruitment for Ph2b wAMD trial
02/07/18	PRICE SENSITIVE	146.94KB	Share
OPT Appendix 3B
27/06/18		159.17KB	Share
OPT Change in substantial holding
30/05/18		117.68KB	Share
OPT Ceasing to be a substantial holder for ANP
11/05/18		96.61KB	Share
OPT Opthea Doses wAMD Patients in Europe and Israel
27/03/18	PRICE SENSITIVE	73.52KB	Share
OPT Opthea Half Year Report and Accounts
19/02/18	PRICE SENSITIVE	449.32KB	Share
OPT Appendix 3B
12/01/18		158.82KB	Share
OPT Opthea Corporate Presentation - January 2018
08/01/18		2.64MB	Share
OPT Opthea Receives A$2.7m R&D Tax Incentive
08/01/18	PRICE SENSITIVE	65.84KB	Share
OPT Opthea Initiates OPT-302 Diabetic Macular Edema Trial
03/01/18	PRICE SENSITIVE	398.83KB	Share
OPT Change in substantial holding
22/12/17		170.88KB	Share
OPT Change in substantial holding (Full copy)
19/12/17		1.04MB	Share
OPT Opthea Doses First Patient in OPT-302 wAMD Ph2b trial
19/12/17	PRICE SENSITIVE	302.75KB	Share
OPT Change in substantial holding
19/12/17		1003.26KB	Share
OPT Appendix 3B
15/12/17		162.11KB	Share
OPT Results of Meeting
23/11/17		40.86KB	Share
OPT Opthea CEO Presentation to the 2017 AGM
23/11/17		2.02MB	Share
OPT Opthea Chairman's Address to the 2017 AGM
23/11/17		71.99KB	Share
OPT Appendix 3B
21/11/17		162.29KB	Share
OPT Notice of Annual General Meeting and Proxy Form
23/10/17		884.19KB	Share
OPT Opthea Granted Key United States Patent Covering OPT-302
31/08/17	PRICE SENSITIVE	73.63KB	Share
OPT Appendix 4G and Corporate Governance Statement 2017
30/08/17		268.62KB	Share
OPT Opthea Appendix 4E and Annual Report 2017
30/08/17	PRICE SENSITIVE	6.7MB	Share
OPT Opthea Presents Further Positive Data from OPT-302 Ph1/2A
15/08/17	PRICE SENSITIVE	260.85KB	Share
OPT Opthea presentation for Ophthalmology Innovation Summit
11/08/17		1.18MB	Share
OPT Opthea Presents at the Ophthalmology Innovation Summit
11/08/17		302.32KB	Share
OPT Opthea to present at the ASRS Annual Meeting and the OIS
09/08/17		261.52KB	Share
OPT Opthea to Present at Wedbush PacGrow Conference
01/08/17		65.34KB	Share
OPT Opthea Allowed Key Patent for OPT-302 in United States
06/07/17	PRICE SENSITIVE	75.74KB	Share
OPT Appendix 3B
30/06/17		147.89KB	Share
OPT Change of Director's Interest Notice - GK
09/05/17		76.41KB	Share
OPT Change of Director's Interest Notice - MB
09/05/17		88.64KB	Share
OPT Appendix 3B
03/05/17		155.8KB	Share
OPT Opthea Completes A$45 Million Capital Raising
28/04/17	PRICE SENSITIVE	74.07KB	Share
OPT Change of Director's Interest Notice - MS
27/04/17		88.27KB	Share
OPT Ceasing to be a substantial holder
21/04/17		131.77KB	Share
OPT Change in substantial holding
18/04/17		6.39MB	Share
OPT Placement Cleansing Statement
12/04/17		54.18KB	Share
OPT Appendix 3B
12/04/17		221.2KB	Share
OPT Opthea Entitlement Offer Notice to Ineligible Shareholders
10/04/17		90.11KB	Share
OPT Opthea Retail Entitlement Offer Booklet
10/04/17		14.78MB	Share
OPT ASX Notice - Accelerated Non-Renounceable Entitlement Offer
05/04/17		364KB	Share
OPT Opthea Successfully Completes Institutional Capital Raising
05/04/17	PRICE SENSITIVE	277.24KB	Share
OPT Entitlement Offer Cleansing Statement
03/04/17		92.52KB	Share
OPT Appendix 3B
03/04/17		222.98KB	Share
OPT Opthea A$45M Equity Raising Launch Presentation
03/04/17		902.34KB	Share
OPT Opthea Launches A$45M Financing for Clinical Development
03/04/17	PRICE SENSITIVE	69.48KB	Share
OPT Opthea Phase 1/2A wet AMD Trial Update Presentation
03/04/17		1.57MB	Share
OPT Opthea Reports Positive Phase 1/2A Clinical Results
03/04/17	PRICE SENSITIVE	93.12KB	Share
OPT Trading Halt
03/04/17	PRICE SENSITIVE	281.48KB	Share
OPT Opthea to Host Update on OPT-302 Phase 1/2A wAMD Trial
31/03/17		257.13KB	Share
OPT Trading Halt
30/03/17	PRICE SENSITIVE	269.41KB	Share
OPT Opthea Receives EU Regulatory Feedback for OPT-302 Program
20/03/17	PRICE SENSITIVE	259.56KB	Share
OPT Ceasing to be a substantial holder
13/03/17		104.46KB	Share
OPT Opthea Completes FDA Meeting to Inform OPT-302 Program
09/03/17	PRICE SENSITIVE	259.31KB	Share
OPT Opthea Half Year Report and Accounts
21/02/17	PRICE SENSITIVE	732.82KB	Share
OPT Change in substantial holding
14/02/17		129.15KB	Share
OPT Appendix 3B
06/02/17		154.22KB	Share
OPT Opthea Corporate Presentation during JPMorgan Conference
09/01/17		2.19MB	Share
OPT Results of Meeting
28/11/16		44.23KB	Share
OPT Opthea CEO Presentation to the 2016 AGM
28/11/16		1.75MB	Share
OPT Opthea Chairman's Address to the 2016 AGM
28/11/16		56.28KB	Share
OPT Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial
21/11/16	PRICE SENSITIVE	257.39KB	Share
OPT Notice of Annual General Meeting and Proxy Form-OPT.AX
28/10/16		573.32KB	Share
OPT Opthea receives $2.6M R&D tax incentive-OPT.AX
17/10/16	PRICE SENSITIVE	53.39KB	Share
OPT Appendix 3B-OPT.AX
10/10/16		154.08KB	Share
OPT Opthea Ph1 wAMD data presented at EURETINA 2016-OPT.AX
12/09/16		258.87KB	Share
OPT Appendix 4G and Corporate Governance Statement 2016-OPT.AX
29/08/16		193.92KB	Share
OPT Appendix 4E and Annual Report 2016-OPT.AX
29/08/16	PRICE SENSITIVE	6.82MB	Share
OPT Opthea to Present at Ophthalmology Innovation Summit in US-OPT.AX
08/08/16		301.01KB	Share
OPT Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX
26/07/16	PRICE SENSITIVE	284.72KB	Share
OPT Opthea to Host Conference Call Update on wetAMD Trial-OPT.AX
25/07/16		256.34KB	Share
OPT Change of Director's Interest Notice - MB-OPT.AX
05/07/16		74.93KB	Share
OPT Appendix 3B-OPT.AX
18/05/16		157.11KB	Share
OPT Change in substantial holding from OPT,OPT-ANP.AX
16/05/16		63.23KB	Share
OPT Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD-OPT.AX
05/05/16	PRICE SENSITIVE	270.78KB	Share
OPT Opthea Ph1 wAMD Trial with OPT-302 Meets Primary Objective-OPT.AX
21/04/16	PRICE SENSITIVE	322.48KB	Share
OPT Change of Director's Interest Notice - GK-OPT.AX
07/04/16		76.08KB	Share
OPT Change of Director's Interest Notice - MS-OPT.AX
07/04/16		75.67KB	Share
OPT Change of Director's Interest Notice - MB-OPT.AX
07/04/16		74.15KB	Share
OPT Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial
30/03/16	PRICE SENSITIVE	318.78KB	Share
OPT Results of the Extraordinary General Meeting
07/03/16		81.87KB	Share
OPT CEO's Presentation to the EGM
07/03/16		1.71MB	Share
OPT Chairman's Address to the EGM
07/03/16		53.8KB	Share
OPT Half Year Report and Accounts
26/02/16	PRICE SENSITIVE	943.53KB	Share
OPT Notice of Extraordinary General Meeting/Proxy Form
05/02/16		607.33KB	Share
OPT Becoming a substantial holder
30/12/15		150.8KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $820.7M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED - Announcements

Announcements

Top Stories